Contraception Clinical Trial
Official title:
A Study to Evaluate the Contraceptive Effectiveness, Safety and Acceptability of Sino-implant II
Verified date | September 2017 |
Source | FHI 360 |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to assess the contraceptive effectiveness of Sino-implant (II).
Status | Completed |
Enrollment | 650 |
Est. completion date | July 4, 2017 |
Est. primary completion date | July 4, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 44 Years |
Eligibility |
Inclusion Criteria:• In good general health - Aged between 18 and 44 years, inclusive - Not pregnant - Not lactating - Not wishing to become pregnant in the next five years - Request long-acting reversible contraception - If previously used injectable contraceptives for pregnancy prevention, be more than 9 months since last injection of Depo-Provera and more than 3 months after the last injection of a combined injectable contraceptive - If previously used LNG-containing oral pills or implants, be more than 1 week after last hormone intake or implant removal - Be able to understand the information provided and to make personal decisions on participation - Consent to participation and sign a consent form - Agree and be able to return to the clinic for follow-up visits over five years Exclusion Criteria: - acute deep venous thrombosis and/or pulmonary embolism or history of thromboembolic disease - systemic lupus erythematosus with positive or unknown antiphospholipid antibodies - unexplained vaginal bleeding - current or history of breast cancer - acute liver disease or cirrhosis - benign or malignant tumor of the liver - use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's Wort (Hypericum perforatum) - more than one sexual partner in the last 3 months - diagnosis or treatment for a sexually transmitted infection (STI) within the past 30 days for her or partner (excluding recurrent genital herpes or condyloma) - known HIV positive status for her or partner - any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation - BMI greater than or equal to 30 (for the sub-group of women with intensive LNG sampling) |
Country | Name | City | State |
---|---|---|---|
Dominican Republic | Profamilia | Santo Domingo |
Lead Sponsor | Collaborator |
---|---|
FHI 360 | Bill and Melinda Gates Foundation |
Dominican Republic,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the contraceptive effectiveness of Sino-implant (II) during 4 years of use. | Pearl Index (number of pregnancies per 100 woman-years) over 4 years of use of Sino-implant (II). | 4 years | |
Secondary | Evaluate the contraceptive effectiveness of Sino-implant (II) during 5 years of use | Pearl Index over 5 years of use of Sino-implant (II) ; continuation & reasons for discontinuation in both groups. | 5 years | |
Secondary | Compare concentrations of levonorgestrel through 5 years after insertion of Sino-implant (II) and Jadelle | annual and cumulative probability of pregnancy during 5 years of use of Sino-implant (II); | 5 years | |
Secondary | Compare pharmacokinetic profiles of Sino-implant (II) and Jadelle during the first 6 months of use in a sub-group of users undergoing intensive levonorgestrel sampling | The PK profile of LNG during the first 6 months post-insertion including the following parameters in a sub-group of users undergoing intensive LNG sampling: Mean LNG concentrations at 6 hours, 24 hours, 48 hours, 72 hours, 7 days and 90 days post-insertion Concentration-time profiles of LNG (individual and pooled) Maximal concentration (Cmax) and time to maximal concentration (Tmax) AUC0-7 days, AUC0-1mon, AUC0-3mon and AUC0-6mon |
5 years | |
Secondary | Compare the safety and acceptability of Sino-implant (II) and Jadelle during 5 years of use | Adverse event rates in both treatment groups Annual and cumulative probability of early discontinuation in both treatment groups Reasons for discontinuation in both treatment groups Responses on acceptability questionnaires in both treatment groups | 5 years | |
Secondary | Compare free levonorgestrel index through 5 years after insertion of Sino-implant (II) and Jadelle in a sub-group of approximately 150 users. | free levonorgestrel index, estimated as the ratio of levonorgestrel to sex hormone binding globulin at various point during 5 years of product use in a sub-group of approximately 150 women. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |